Alkermes announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Miami, May 29 – June 1, 2018. The poster presentations will highlight data from the company’s depression and schizophrenia portfolios, including ALKS 5461, ARISTADA and ALKS 3831. Clinical data for ALKS 5461 will be presented, including long-term safety, tolerability and durability of antidepressant effect over a 52-week treatment period in patients with major depressive disorder. In addition, data from a human abuse potential study conducted in healthy, nondependent opioid users will be presented. In the study, ALKS 5461, a combination of buprenorphine with the mu-opioid receptor antagonist samidorphan, posed a low risk of abuse. Alkermes will present data related to ARISTADA, including results from a two-year safety study in patients with schizophrenia, and results from a pharmacokinetic and safety study evaluating Aripiprazole Lauroxil NanoCrystal Dispersion, a novel, investigational product designed for initiation onto ARISTADA. The company will also present results from a phase 2 study of ALKS 3831 in patients with schizophrenia and co-occurring alcohol use disorder
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.